×

Novo Nordisk A/S: Xultophy(r) (IDegLira) approved in Europe

BAGSVAERD, Denmark, Sept. 18, 2014 (GLOBE NEWSWIRE) -- Novo Nordisk today announced that the European Commission has granted marketing authorisation for Xultophy® for the treatment of type 2 diabetes mellitus in adults. The authorisation covers all 27 European Union member states.

For further information

Media:
Mike Rulis +45 3079 3573 mike@novonordisk.com
Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com
Investors:
Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com
Jannick Lindegaard Denholt +45 3079 8519 jlis@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com

Company announcement No 58 / 2014

Company announcement No 58 / 2014 http://hugin.info/2013/R/1856969/650059.pdf

HUG#1856969

Source:Novo Nordisk A/S